Category Archives: AZBio News

Banner Health urges former COVID-19 patients to donate plasma for current patients

Posted on by

Banner Research provides Donation Coordinators to assist potential donors

PHOENIX (April 24, 2020) – With the need for “convalescent plasma” to treat critically ill COVID-19 patients ramping up as cases rise, Banner Research is providing donation coordinators in metro Phoenix, Tucson and Northern Colorado to help recovered COVID-19 patients get through the plasma donation process. The donation coordinators are equipped to assess qualifying criteria for potential donors, answer questions and explain how the donation process works.Continue reading→

Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company’s Goal to Supply More Than One Billion Vaccine Doses Globally

Posted on by

Company Signs Agreement with Emergent BioSolutions in the U.S. As Part of its Investment

First in Series of Anticipated Strategic Collaborations Designed to Further the Company’s Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19Continue reading→

Pathogen and Microbiome Institute at NAU to test the antiviral activity of 2X-121, a Danish Company’s PARP inhibitor, against Coronavirus

Posted on by

Hørsholm, Denmark (April 22nd, 2020) – Oncology Venture A/S (“OV” or the Company) today announced that it has entered into an agreement with the Pathogen and Microbiome Institute at Northern Arizona University (NAU) to test the antiviral activity of 2X-121, its PARP inhibitor, against Coronavirus.Continue reading→

Accelerate Diagnostics and BioCheck Announce Commercial Supply and Collaboration Agreement to Distribute MS-FAST Chemiluminescence Immunoassay Analyzer and SARS-CoV-2 Antibody Tests

Posted on by
TUCSON, Ariz., — Accelerate Diagnostics, Inc. (NASDAQ:AXDX) and BioCheck, Inc., a privately-held San Francisco-based company focused on in vitro diagnostics, today announced that they have entered into a commercial supply and collaboration agreement. Under the agreement, Accelerate Diagnostics will distribute the BioCheck MS-FAST, a fully-automated chemiluminescence immunoassay analyzer, along with BioCheck’s SARS-CoV-2 tests for the detection of IgG and IgM antibodies. The agreement covers North America, Europe and the Middle East.

Continue reading→

Novel coronavirus detected, monitored in wastewater

Posted on by

Within weeks of arriving on the world stage, SARS-CoV-2 has managed to encircle the globe, leaving illness, mortality and economic devastation in its vast wake. One of the central challenges facing health authorities and the medical community has been testing for the elusive virus on a sufficiently comprehensive scale.

A new approach to monitoring the novel coronavirus, (as well as other dangerous pathogens and chemical agents), is being developed and refined. Known as wastewater-based epidemiology (WBE), the method mines sewage samples for vital clues about human health. It can potentially identify levels of coronavirus infection at both a local and global scale.Continue reading→

Quest Diagnostics Begins to Perform COVID-19 Antibody Testing

Posted on by

SECAUCUS, N.J., April 21, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has begun to perform antibody testing for coronavirus (COVID-19) using blood samples. With the new service, Quest Diagnostics now provides healthcare providers in the United States access to COVID-19 antibody as well as molecular diagnostic laboratory testing.  Continue reading→

C-Path Awarded FDA Contract to Enhance the Assessment of Clinical Outcomes in Pediatric Asthma Treatment Trials

Posted on by

Resulting novel drug development tools will support patient-focused drug development for children with asthma

 

 

TUCSON, Ariz., April 21, 2020 — The Critical Path Institute (C-Path) announced today it has been awarded a U.S. Food and Drug Administration (FDA) contract in support of ongoing development of novel clinical outcome assessments for pediatric asthma. C-Path’s Patient-Reported Outcome (PRO) Consortium will carry out this work through its Pediatric Asthma Working Group. Specifically, these assessments are intended to facilitate innovative patient-focused drug development and aid regulatory decision making by filling an unmet measurement gap.Continue reading→